Friday, July 10, 2026
🇺🇸 FDA

Intelligence · INN directory

Immunology Drugs Directory

Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.

Drugs in segment 63
Companies 1,771
Pipeline programs 20,548

Quick answer

Immunology & autoimmune drugs: NovaPharmaNews indexes 63 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.

63 drugs · Immunology & autoimmune drugs · by data quality · Page 2 of 3

  1. nogapendekin alfa inbakicept-pmln

    ANKTIVA

    INTRAVESICAL FDA: approved

  2. risankizumab-rzaa

    SKYRIZI

    INJECTION FDA: approved

  3. ruxolitinib

    JAKAVI Novartis Pharmaceuticals

    ORAL FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    D11AH

  4. ruxolitinib phosphate

    JAKAFI XR

    TOPICAL FDA: approved

  5. sarilumab

    KEVZARA

    INJECTION FDA: approved · EMA: approved · PMDA: approved

    L04AC14

  6. secukinumab

    COSENTYX Novartis Pharmaceuticals

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    L04AC10

  7. siltuximab

    SYLVANT Recordati Rare Diseases Australia Pty.

    INJECTION FDA: approved · EMA: approved · TGA: approved

    L04AC11

  8. tildrakizumab-asmn

    ILUMYA

    INJECTION FDA: approved

  9. tocilizumab

    ACTEMRA Hoffmann-La Roche

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    L04AC07

  10. tocilizumab-aazg

    TYENNE

    SUBCUTANEOUS FDA: approved

  11. tocilizumab-bavi

    TOFIDENCE

    INJECTION FDA: approved

  12. tofacitinib

    XELJANZ Pfizer Australia Pty Ltd

    ORAL FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    L04AF01

  13. tofacitinib citrate

    XELJANZ INITIAL APPROVAL

    ORAL FDA: approved · PMDA: approved

  14. tralokinumab

    ADTRALZA

    INJECTION FDA: approved · EMA: approved

    D11

  15. ustekinumab

    STELARA Janssen-Cilag Pty Ltd

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    L04AC05

  16. ustekinumab-aekn

    SELARSDI

    INJECTION FDA: approved

  17. ustekinumab-ttwe

    PYZCHIVA

    INJECTION FDA: approved

  18. bimekizumab

    BIMZELX

    EMA: approved

    L04AC

  19. briakinumab

    OZESPA

    EMA: application withdrawn

    L04AC09

  20. depemokimab

    EXDENSUR

    EMA: approved

    R03DX12

  21. fedratinib

    INREBIC Bristol-Myers Squibb Australia Pty Ltd

    EMA: approved · TGA: approved

    L01EJ02

  22. filgotinib

    JYSELECA

    EMA: approved

    L04AF04

  23. mirikizumab

    OMVOH

    EMA: approved · PMDA: approved · NMPA: clinical trials

    L04AC

  24. momelotinib

    OMJJARA GlaxoSmithKline

    EMA: approved · TGA: approved

Frequently asked questions

How many immunology & autoimmune drugs are in the directory?

63 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.

How are drugs assigned to a therapeutic area?

Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.

Where does regulatory data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.